Literature DB >> 12053225

Pain management of patients with unresectable peripancreatic carcinoma.

Rutger C I van Geenen1, Claudia M G Keyzer-Dekker, Geertjan van Tienhoven, Huug Obertop, Dirk J Gouma.   

Abstract

In patients with unresectable peripancreatic carcinoma, pain is generally treated with pain medication or with a celiac plexus blockade. Radiotherapy has also been reported to reduce pain. The efficacy of these treatment modalities is still under discussion. The aim of this study was to analyze the effects of the various types of pain management on patients who underwent palliative bypass surgery for unresectable peripancreatic carcinoma. During the period January 1995 to December 1998 a series of 98 patients underwent palliative bypass surgery, mostly for unresectable disease found during exploration. Patients were divided into three groups: palliative bypass surgery (BP), palliative bypass surgery with an intraoperative celiac plexus blockade (CPB), and palliative bypass surgery with or without celiac plexus blockade followed by high-dose conformal radiotherapy (RT). Radiotherapy was performed only in selected patients with locally advanced disease and without metastases, implying a better prognosis of the last group. The pain medication consumption, pain medication-free survival, hospital-free survival, and overall survival were analyzed. The preoperative consumption of pain medication was significantly higher in the CPB group than in the BP or RT group. The postoperative consumption of pain medication in the CPB, BP, and RT groups increased during follow-up from 15%, 17%, and 13% before surgery to 52%, 57%, and 46%, respectively, at three-fourths of the survival time (NS). This increase in consumption of pain medication was not different in the three groups. In the RT group the median pain medication-free survival was significantly longer than in the BP or CPB group (9.3 vs. 3.1 and 3.3 months; p = 0.02). The median hospital-free survival and median overall survival were significantly longer in the RT group than in the CPB group (10.3 vs. 6.8 months, p = 0.01; and 7.1 vs. 10.8 months, p = 0.01). Celiac plexus blockade as pain management did not result in an increase of the pain medication-free survival or overall survival. Therefore a positive effect of a celiac plexus blockade on pain could not be confirmed in the present study. Radiotherapy resulted in increased pain-medication survival, hospital-free survival, and overall survival compared to celiac plexus blockade. These effects are probably partly related to patient selection.

Entities:  

Mesh:

Year:  2002        PMID: 12053225     DOI: 10.1007/s00268-002-6210-2

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  27 in total

1.  Pain as a predictor of outcome in patients with operable pancreatic carcinoma.

Authors:  D P Kelsen; R Portenoy; H Thaler; Y Tao; M Brennan
Journal:  Surgery       Date:  1997-07       Impact factor: 3.982

2.  Prospective randomized double-blind trial of neurolytic coeliac plexus block in patients with pancreatic cancer.

Authors:  E Polati; G Finco; L Gottin; C Bassi; P Pederzoli; S Ischia
Journal:  Br J Surg       Date:  1998-02       Impact factor: 6.939

Review 3.  Pancreatic carcinoma.

Authors:  S Rosewicz; B Wiedenmann
Journal:  Lancet       Date:  1997-02-15       Impact factor: 79.321

4.  The role of radiation therapy in the control of pain from pancreatic carcinoma.

Authors:  B D Minsky; B Hilaris; Z Fuks
Journal:  J Pain Symptom Manage       Date:  1988       Impact factor: 3.612

Review 5.  Palliative and supportive care of patients with pancreatic cancer.

Authors:  C L Alter
Journal:  Semin Oncol       Date:  1996-04       Impact factor: 4.929

6.  Outcome of palliative biliary and gastric bypass surgery for pancreatic head carcinoma in 126 patients.

Authors:  B A van Wagensveld; P P Coene; T M van Gulik; E A Rauws; H Obertop; D J Gouma
Journal:  Br J Surg       Date:  1997-10       Impact factor: 6.939

Review 7.  Pain management of pancreatic cancer.

Authors:  A Andrén-Sandberg; A Viste; A Horn; D Hoem; H Gislason
Journal:  Ann Oncol       Date:  1999       Impact factor: 32.976

Review 8.  Pancreatic pain: is there a medical alternative to surgery?

Authors:  I Ihse; R Andersson; J Axelson
Journal:  Digestion       Date:  1993       Impact factor: 3.216

9.  Guidelines for the application of surgery and endoprostheses in the palliation of obstructive jaundice in advanced cancer of the pancreas.

Authors:  R P van den Bosch; G P van der Schelling; J H Klinkenbijl; P G Mulder; M van Blankenstein; J Jeekel
Journal:  Ann Surg       Date:  1994-01       Impact factor: 12.969

10.  Interstitial iodine-125 implant in the management of unresectable pancreatic carcinoma.

Authors:  A M Syed; A A Puthawala; D L Neblett
Journal:  Cancer       Date:  1983-09-01       Impact factor: 6.860

View more
  7 in total

1.  Neoadjuvant chemoradiotherapy has a potential role in pancreatic carcinoma.

Authors:  Geertjan van Tienhoven; Dirk J Gouma; Dick J Richel
Journal:  Ther Adv Med Oncol       Date:  2011-01       Impact factor: 8.168

2.  The need for a prophylactic gastrojejunostomy for unresectable periampullary cancer: a prospective randomized multicenter trial with special focus on assessment of quality of life.

Authors:  N Tjarda Van Heek; Steve M M De Castro; Casper H van Eijck; Rutger C I van Geenen; Eric J Hesselink; Paul J Breslau; T C Khe Tran; Geert Kazemier; Mechteld R M Visser; Olivier R C Busch; Hugo Obertop; Dirk J Gouma
Journal:  Ann Surg       Date:  2003-12       Impact factor: 12.969

3.  Pancreatic carcinoma: palliative surgical and endoscopic treatment.

Authors:  D J Gouma; O R C Busch; T M Van Gulik
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

Review 4.  Pancreas Cancer-Associated Pain Management.

Authors:  Andrew L Coveler; Jonathan Mizrahi; Bory Eastman; Smith Jim Apisarnthanarax; Shalini Dalal; Terry McNearney; Shubham Pant
Journal:  Oncologist       Date:  2021-05-12

5.  Perioperative high dose rate (HDR) brachytherapy in unresectable locally advanced pancreatic tumors.

Authors:  Dariusz Waniczek; Jerzy Piecuch; Marek Rudzki; Wojciech Mikusek; Jerzy Arendt; Brygida Białas
Journal:  J Contemp Brachytherapy       Date:  2011-07-06

6.  Prognosis and survival analysis of patients with pancreatic cancer: retrospective experience of a single institution.

Authors:  Qi Li; Zijian Feng; Ruyi Miao; Xun Liu; Chenxi Liu; Zhen Liu
Journal:  World J Surg Oncol       Date:  2022-01-07       Impact factor: 2.754

7.  Pain management in pancreatic cancer.

Authors:  Mariam Hameed; Haroon Hameed; Michael Erdek
Journal:  Cancers (Basel)       Date:  2010-12-24       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.